The University of Chicago Header Logo

Connection

Dejan Micic to Inflammatory Bowel Diseases

This is a "connection" page, showing publications Dejan Micic has written about Inflammatory Bowel Diseases.
Connection Strength

5.190
  1. Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis. Gastroenterology. 2022 Jan; 162(1):88-108.e9.
    View in: PubMed
    Score: 0.822
  2. Nutrition Considerations in Inflammatory Bowel Disease. Nutr Clin Pract. 2021 Apr; 36(2):298-311.
    View in: PubMed
    Score: 0.790
  3. Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 04; 63(4):1016-1024.
    View in: PubMed
    Score: 0.639
  4. Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. PLoS One. 2017; 12(8):e0182900.
    View in: PubMed
    Score: 0.619
  5. Factors associated with poor compliance amongst hospitalized, predominantly adolescent pediatric Crohn's disease patients. Ann Med. 2022 12; 54(1):886-892.
    View in: PubMed
    Score: 0.223
  6. Endo-histologic Normalization Is Achievable with Tofacitinib and Is Associated with Improved Clinical Outcomes. Dig Dis Sci. 2023 04; 68(4):1464-1472.
    View in: PubMed
    Score: 0.221
  7. Review article: drug-induced small bowel injury. Aliment Pharmacol Ther. 2021 12; 54(11-12):1370-1388.
    View in: PubMed
    Score: 0.206
  8. Risk of Cancers in Patients with Pediatric Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. J Pediatr. 2021 02; 229:102-117.e36.
    View in: PubMed
    Score: 0.191
  9. Drug-Induced Colitis. Clin Gastroenterol Hepatol. 2021 09; 19(9):1759-1779.
    View in: PubMed
    Score: 0.186
  10. Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents. Aliment Pharmacol Ther. 2019 08; 50(4):373-385.
    View in: PubMed
    Score: 0.176
  11. Risk of Fractures in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2019 07; 53(6):441-448.
    View in: PubMed
    Score: 0.176
  12. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
    View in: PubMed
    Score: 0.176
  13. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019 02; 17(3):486-493.
    View in: PubMed
    Score: 0.162
  14. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018 Mar; 47(6):753-762.
    View in: PubMed
    Score: 0.159
  15. Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply. Aliment Pharmacol Ther. 2017 05; 45(10):1372.
    View in: PubMed
    Score: 0.151
  16. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-a agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017 04; 45(8):1043-1057.
    View in: PubMed
    Score: 0.150
  17. Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. J Crohns Colitis. 2016 Dec; 10(12):1385-1394.
    View in: PubMed
    Score: 0.142
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.